Prophylactic nicotinamide treatment protects from rotenone-induced neurodegeneration by increasing mitochondrial content and volume.

"Declarations Ethics approval and consent to participateAll breeding and experimental procedures were performed in accordance to the Association for Research for Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Research. Individual study protocols were approved by Stockholm’s Committee for Ethical Animal Research (10389–2018). Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding Open access funding provided by Karolinska Institute. This research was funded by Vetenskapsrådet 2018–02124, 2022–00799 (PAW), Ögonfonden (PAW), Stiftelsen Kronprinsessan Margaretas Arbetsnämnd för Synskadade (PAW), Karolinska Institutet Foundation Grants for Eye Research (PAW, JRT), and Karolinska Institutet Research Foundation Grants (PAW, JRT). PAW is an Alcon Research Institute Young Investigator. PAW is supported by Karolinska Institutet in the form of a Board of Research Faculty Funded Career Position and by St. Erik Eye Hospital philanthropic donations."